Related Experiment Videos
5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists
Hiroo Koyama1, Julia K Boueres, Wei Han
1Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065-0900, USA. hiroo_koyama@merck.com
Bioorganic & Medicinal Chemistry Letters
|May 6, 2003
Abstract:
A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.